Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 10;16(5):847–856. doi: 10.1016/j.jcmgh.2023.08.003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

GLP-2 treatment increases NR4a1/Nur77 expression and nuclear binding in human hepatic stellate cells in vitro. (A) Real-time polymerase chain reaction was used to assess the mRNA expression of NR4a1/Nur77 in the human hepatic stellate cell line LX-2. Tgfβ-induced suppression of NR4a1/Nur77 could be counteracted by GLP-2 treatment. mRNA expression values were normalized against 36b4 levels and are shown relative to expression level in untreated control cells. ∗Significant difference from untreated control (Ctrl) cells. ^#Significant difference from Tgfβ-treated cells. P < .05. (B) Representative electrophoretic mobility shift assay demonstrated that GLP-2 treatment increases the nuclear binding of NR4A1/NUR77, whereas Tgfβ challenge led to a reduction of the NR4A1/NUR77 nuclear binding. Of note, GLP-2 treatment was able to counteract the Tgfβ-related reduction of the NR4A1/NUR77 nuclear binding. Ab, antibody; C, cytoplasmatic protein fraction; N, nuclear protein fraction.